Peer-influenced content. Sources you trust. No registration required. This is HCN.

HealioSURMOUNT-1: Adults Achieve Weight Loss of 16% or More at 72 Weeks with Tirzepatide

Clinical trials of a new weight loss medication have found that adults with obesity taking the once-weekly GIP/GLP-1 receptor agonist tirzepatide achieved a mean weight loss of at least 16% at 72 weeks. Most side effects observed were mild to moderate, with the most common being nausea, diarrhea, constipation, and vomiting. The results are considered encouraging.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form